CD70-targeted cars and engineered cells comprising same and related methods

TW202641831APending Publication Date: 2026-10-16JUNO THERAPEUTICS INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
TW114150315
Authority / Receiving Office
TW · TW
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-08
Filing Date
2025-12-19
Publication Date
2026-10-16

Smart Images

  • Figure TWG2TA001080771_001
    Figure TWG2TA001080771_001
  • Figure TWG2TA001080771_002
    Figure TWG2TA001080771_002
  • Figure TWG2TA001080771_003
    Figure TWG2TA001080771_003
Patent Text Reader

Abstract

Provided herein are CD70-targeted chimeric antigen receptors (CARs), genetically engineered cells such as T cells containing the same, and related methods and uses of the genetically engineered cells in allogeneic cell therapy. Also provided are T cells that are genetically engineered with a CAR, such as a CD70-targeted CAR, and are further genetically engineered by one or more strategies to reduce host immune recognition of the engineered T cells, such as by heterologous expression of one or more additional transgenes and by genetic disruption to reduce or eliminate expression or one or more endogenous protein. Also provided are methods of making and using the engineered T cells for cell therapy, including in connection with cancer immunotherapy comprising adoptive transfer of the engineered T cells.
Need to check novelty before this filing date? Find Prior Art